Programming - BCVS Scientific Sessions 2022
July 25–28, 2022
Chicago Hilton | Chicago, Illinois
About this Meeting
The 16th annual BCVS 2022 Scientific Sessions has become the premier conference for molecular cardiovascular biology and disease. Sponsored by the American Heart Association Basic Cardiovascular Sciences Council, the world’s leading organization of cardiovascular scientists, the conference attracts leading researchers in fields such as microRNAs, cardiac gene and cell therapy, cardiac development and most recently tissue engineering and iPS cells.
BCVS 2022 Final Program
TIME (Central Time) | ACTIVITY |
---|---|
8:00 a.m. – 8:45a.m | AHA Research Overview Glenn Dillon, PhD | American Heart Association |
9:00 a.m. – 9:15 a.m. | Early Career Opening Remarks Susmita Sahoo, PhD | Mount Sinai School of Medicine Sarah Schumacher-Bass, PhD | Cleveland Clinic |
9:15 a.m. – 10:15 a.m. |
Early Career Session 1: Next Best Thing in Cardiovascular Research
|
10:15 a.m. – 10:45 a.m. | Break/Exhibits |
10:45 a.m. – 11:45 a.m. |
Early Career Session 2: Next Best Thing in Cardiovascular Research
|
11:45 a.m. – 12:30 p.m. | Early Career Keynote Address Ivor Benjamin, MD, FACC, FAHA | Medical College of Wisconsin Moderator: Sean Wu, MD, PhD, Stanford University |
12:30 p.m. – 1:00 p.m. | Break/Exhibits |
1:00 p.m. – 1:30 p.m. |
Opening Welcome Opening Remarks from the President of the American Heart Association Welcome Remarks from the BCVS Leadership Committee Chair |
1:30 p.m. – 2:45 p.m. |
Session 1: Genetic Basis of Cardiomyopathy
|
2:45 p.m. – 3:15 p.m. | Break/Exhibits |
3:15 p.m. – 4:30 p.m. |
Session 2: Cardiac Repair, Cellular Reprogramming and Tissue Engineering
|
4:30 p.m. – 7:00 p.m. | Poster Session 1 (Includes Poster Competition) |
TIME (Central Time) | ACTIVITY |
---|---|
7:00 a.m. – 8:00 a.m. | Continental Breakfast |
7:00 a.m. – 8:00 a.m. |
Women in Science Breakfast
|
8:00 a.m. – 9:15 a.m. |
Session 3: Small RNAs, Exosomes and Extracellular Vesicles in Cardiovascular Disease
|
9:15 a.m. – 9:45 a.m. | Refreshment Break/Exhibits |
9:45 a.m. – 11:00 a.m. |
Session 4: Advances in Cardiac Hypertrophy and Remodeling
|
11:00 a.m. - Noon |
Session 5: Keynote Lecture
|
Noon – 1:30 p.m. | Lunch on Your Own/Poster Viewing/Exhibits Or BCVS Early Career: Lunch with Legends * Ticketed event for Early Career members to meet invited senior investigators. Table Leaders: Sean Wu, MD PhD, Stanford University Sakthi Sadayappan, PhD, University of Cincinnati Jill Tardiff, PhD, University of Arizona Susmita Sahoo, PhD, Mount Sinai Åsa Gustafsson, PhD, UC San Diego Steve Jones, PhD, University of Louisville Sarah Schumacher, PhD, Cleveland Clinic Elizabeth McNally, MD, PhD, Northwestern University Jonathan Kirk, PhD, Loyola University Chicago Rong Tian, PhD, University of Washington Xinliang Ma, PhD, Thomas Jefferson University2 Young-sup Yoon, MD, PhD, Emory University Nicole Purcell, PhD, Huntington Medical Research Institutes Robin Shaw, MD, PhD, University of Utah |
1:30 p.m. – 2:45 p.m. |
Session 6: Hot Topics in Cardiac Fibrosis
|
2:45 p.m. – 3:15 p.m. | Refreshment Break/Exhibits |
3:15 p.m. – 4:30 p.m. |
Session 7: Bench to Bedside: Cardiovascular Therapeutics not Lost in Translation
|
4:30 p.m. – 7:00 p.m. | Poster Session 2 (Includes Poster Competition) |
7:00 p.m. | Early Career Social |
TIME (Central Time) | ACTIVITY |
---|---|
7:00 a.m. – 8:00 a.m. | Continental Breakfast/Registration/Exhibits |
8:00 a.m. – 9:15 a.m. |
Session 8: Novel Mechanisms of HFpEF and HFrEF
|
9:15 a.m. – 9:45 a.m. | Refreshment Break/Exhibits |
9:45 a.m. – 11:00 a.m. |
Session 9: The Heart and Cancer: New Insight
|
11:00 a.m. – 11:45 a.m. |
Session 10: Outstanding Early Career Investigator Award Competition
|
11:45 a.m. – 1:30 p.m. | Lunch on Your Own Or AHA Center for Accelerated Drug Discovery |
1:30 p.m. – 2:45 p.m. |
Session 11: Metabolic Cues in Heart Disease
|
2:45 p.m. – 3:15 p.m. | Refreshment Break/Exhibits |
3:15 p.m. – 4:30 p.m. |
Session 12: Epigenetics and Transcriptional Control of Heart Disease
|
4:30 p.m. – 7:00 p.m. | Poster Session 3 (Includes Poster Competition) |
7:00 – 9:00 pm | Council Dinner |
TIME (Central Time) | ACTIVITY |
---|---|
7:00 a.m. – 8:00 a.m. | Continental Breakfast |
8:00 a.m. – 9:15 a.m. |
Session 13: Cardio-immunology, Inflammation and Cardiac Pathophysiology
|
9:15 a.m. – 9:45 a.m. | Refreshment Break |
9:45 a.m. – 11:00 a.m. |
Session 14: Interorgan Communications in Heart Disease
|
11:00 a.m. | Adjourn |
Early Career Keynote Speaker: Ivor Benjamin, MD, FACC, FAHA, Medical College of Wisconsin
Date and Time: July 25, 2022, 11:45 a.m.–12:30 p.m.
Dr. Benjamin received his MD from Johns Hopkins University School of Medicine, internship, and residency in Internal Medicine at Yale University School of Medicine, and received fellowship training in Clinical Cardiology, Molecular Cardiology, and Molecular Biology at the University of Chicago (Michael Reese Hospital), Duke University Medical Center, and University of Texas Southwestern Medical Center in Dallas. As director of the Cardiovascular Center at the Medical College of Wisconsin since 2013 and Professor of Medicine at MCW and Froedtert Hospital, Ivor Benjamin, MD brings more than 25 years of experience leading cardiovascular clinical and research programs. Dr. Benjamin’s leadership of the Cardiovascular Center at the Medical College of Wisconsin is increasing the investigative workforce as Co-Director of an NHLBI T32 training program. Dr. Benjamin is the recipient of numerous medical honors, including the Pioneer Award of the National Institutes of Health and the Dr. Daniel D. Savage Memorial Service Award of the Association of Black Cardiologists.
With more than 30 years of volunteer history with the American Heart Association, he proudly served as President from 2018-2019, and then Immediate Past President from 2019-2020. A highly regarded physician-scientist of molecular cardiovascular remodeling, he was an AHA Established Investigator, a founding member of the Journal of the American Heart Association and currently serves on the editorial boards of Circulation and Circulation Research. As chair of the American Heart Association research committee from 2015-17, he expanded opportunities in research for women, minorities, and undergraduates. Dr. Benjamin is a member of its Board of Directors, Corporate Operations Coordinating Committee, Executive Committee, International Committee and Science & Advisory Coordinating Committee. He is also a longtime member of the association’s Council on Basic Cardiovascular Sciences and Council on Clinical Cardiology.
Keynote Speaker: Leslie Leinwand, PhD, University of Colorado
Presentation: From Bench to Bedside: The Role of Science in Treating a Deadly Disease
Date and Time: July 26, 2022, 11 a.m.-12 p.m.
Dr. Leslie Leinwand is a Molecular, Cellular, and Developmental Biology (MCDB) Distinguished Professor and the Chief Scientific Officer of the BioFrontiers Institute at the University of Colorado Boulder. She received her Bachelor’s degree from Cornell University and her PhD from Yale University, and completed her post-doctoral training at Rockefeller University. She joined the faculty at Albert Einstein College of Medicine in New York in 1981 and remained there until moving to Colorado in 1995 to be Chair of MCDB. She co-founded Myogen, Inc. which was sold to Gilead Pharmaceuticals. More recently, she was a co-founder of Hiberna, Inc, and of MyoKardia, Inc, a company founded to develop therapeutics for inherited cardiomyopathies. Bristol Myers Squibb acquired MyoKardia in late 2020.
Leslie is a Fellow of the AAAS, former MERIT Awardee of the NIH, Established Investigator of the American Heart Association, elected member of the American Academy of Arts and Sciences and the National Academy of Inventors, and she serves on the International Council for the International Society for Heart Research. She has been honored by the American Heart Association with its Distinguished Scientist Award.
Dr. Leinwand’s research focuses on the genetics and molecular physiology of inherited diseases of the heart and skeletal muscle, and how biological sex modifies heart and skeletal muscle. The study of these diseases has required multidisciplinary approaches, involving biophysics, molecular biology, mouse genetics, cardiac physiology, and the analysis of human tissues.
Additional Resources
Download these helpful PDFs:
Target Audience
- Basic cardiovascular scientists
- Molecular/cellular biologists
- Physiologists
- Translational investigators
- Clinical trialists
- Practicing cardiologists
- Cardiovascular nurses and pharmacists
Learning Objectives
- Understand new developments in cardiovascular pathophysiology and their implications for future therapeutics.
- Discuss emerging translational research in preventing and treating cardiovascular disease and its precursors.
- Recognize the basis of cardio-immunology and the link to cardio-oncology.
- Describe about current knowledge about, ongoing research into, and research and clinical gaps around the bidirectional relationship between cardiovascular disease and COVID-19.